Evidence map›Paper›PMID 28272347›Full record

ReviewInternational journal of molecular sciences2017

Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.

Delphine Dayde, Ichidai Tanaka, Rekha Jain, Mei Chee Tai, Ayumu Taguchi

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 109 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03962088 unknown statusnot on this mapstarted 2019, after this paper: background citation

Timing To Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy For Rectal Cancer: A Multicenter Randomized Controlled Trial - Biomarkers SubStudy

TypeobservationalSponsorAzienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di AlessandriaRan2019 to 2025Enrolled200ConditionsRectal CancerArmsmiRNA
NCT04927897 recruitingnot on this mapstarted 2022, after this paper: background citation

DETECT: Defining the Target Volume for Endoluminal Radiation Boosting in Patients With Rectal Cancer

TypeobservationalSponsorMaastricht Radiation OncologyRan2022 to 2027Enrolled50ConditionsRectal CancerArmsUltrasound, Rectoscopy, Scan, e.g. CT (resection specimen)
3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Cell-free DNA and preoperative chemoradiotherapy for rectal cancer: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Prognostic Significance ofBiomedicines · 2025
    Article
  17. Article
  18. Pre-TreatmentCancers · 2025
    Article
  19. Article
  20. Observational

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Delphine DaydeDepartments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. DADayde@mdanderson.org.
Ichidai TanakaDepartments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. ITanaka@mdanderson.org.
Rekha JainDepartments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. RJain2@mdanderson.org.
Mei Chee TaiDepartments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. MTai1@mdanderson.org.
Ayumu TaguchiDepartments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. ataguchi@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The standard of care in locally advanced rectal cancer is neoadjuvant chemoradiation (nCRT) followed by radical surgery. Response to nCRT varies among patients and pathological complete response is associated with better outcome. However, there is a lack of effective methods to select rectal cancer patients who would or would not have a benefit from nCRT. The utility of clinicopathological and radiological features are limited due to lack of adequate sensitivity and specificity. Molecular biomarkers have the potential to predict response to nCRT at an early time point, but none have currently reached the clinic. Integration of diverse types of biomarkers including clinicopathological and imaging features, identification of mechanistic link to tumor biology, and rigorous validation using samples which represent disease heterogeneity, will allow to develop a sensitive and cost-effective molecular biomarker panel for precision medicine in rectal cancer. Here, we aim to review the recent advance in tissue- and blood-based molecular biomarker research and illustrate their potential in predicting nCRT response in rectal cancer.

Indexed as

BiomarkersChemoradiotherapyDNA MethylationDNA, NeoplasmGene Expression ProfilingHumansMetabolomicsMicroRNAsMutationNeoadjuvant TherapyPolymorphism, Single NucleotidePrognosisProteomeProteomicsRectal NeoplasmsTranscriptomeBiomarkersDNA, NeoplasmMicroRNAsProteomebiomarkerneoadjuvant chemoradiationrectal cancer

Identifiers

PMID28272347
PMCPMC5372589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.